At the Athena Oncology leadership meeting, Brian Decker presented two significant projects to Athena practice leaders, highlighting EMOL Health’s commitment to advancing care in complex hematologic conditions.
The first project focused on innovative strategies for managing relapsed or refractory multiple myeloma, a challenging stage of the disease where patients require new therapeutic approaches after standard treatments lose effectiveness. Brian Decker discussed the latest advancements in treatment options, including the integration of novel therapies and the importance of early referral for advanced interventions, which has shown promise in improving outcomes for high-risk patients.
The second project centered on the use of JAK-inhibitor treatments for myelofibrosis (MF), emphasizing how these targeted therapies can address disease progression and improve quality of life for patients with this rare bone marrow disorder. By sharing these projects, Brian Decker fostered collaborative dialogue with Athena practice leaders, aiming to accelerate the adoption of cutting-edge therapies and enhance patient care across the network.